The company is advancing a new treatment for people with Alexander disease.
News & Analysis: Ionis Pharmaceuticals
Both primary as well as multiple secondary endpoints were met in the trial.
The drug will advance to studies in familial chylomicronemia syndrome and other diseases that result in high triglyceride levels.
Investors are overly focused on one issue with this stock while the company is making progress on many fronts.
IONS earnings call for the period ending September 30, 2019.
Aksea Therapeutics is teaming up with Pfizer on a new drug, and HEXO got downgraded after the resignation of its CFO.
A licensing deal gives investors confidence in a turnaround.
Ionis Pharma has some powerful numbers now. But its future opportunities are even more amazing.
IONS earnings call for the period ending June 30, 2019.
Royalties are nice, but licensing, milestone, and option payments are getting it done for this biotech.